A Needle-Free Skin Patch Approach to Delivering Liraglutide for Long-Term Obesity Treatment
Researchers developed nanoparticle-coated liraglutide that can penetrate the skin, potentially eliminating the need for daily injections in obesity treatment.
Quick Facts
What This Study Found
The researchers built a two-step nanoparticle platform using flash nanocomplexation (FNC) technology. Liraglutide was first encapsulated in nanoparticles formed by tannic acid and aluminum ions held together by coordination and hydrogen bonding. These particles were then coated with positively charged hydroxypropyl trimethylammonium chloride chitosan (HTCC) to boost skin penetration.
The resulting nanoparticles demonstrated superior transdermal penetration compared to unformulated liraglutide, produced durable blood-sugar-lowering effects, and showed long-acting therapeutic efficacy against obesity in a mouse model.
Key Numbers
Two-step FNC nanoparticle platform; TA-Al3+ coordination with HTCC coating; superior transdermal penetration; sustained hypoglycemic effects in mice
How They Did This
This was a laboratory and animal study. The researchers used flash nanocomplexation technology to create nanoparticles encapsulating liraglutide, then tested their ability to penetrate skin barriers and produce therapeutic effects in obese mice. The nanoparticles were characterized for size, charge, and stability, then evaluated for transdermal penetration, blood sugar control, and weight management outcomes.
Why This Research Matters
Needle phobia and injection fatigue are real barriers to GLP-1 drug adherence. If liraglutide could be delivered painlessly through the skin, more patients might stick with treatment long-term. This nanoparticle platform could also be adapted for other peptide drugs that currently require injection.
The Bigger Picture
The GLP-1 drug market is booming, but nearly all these medications require injections. Multiple research groups are racing to develop needle-free delivery methods — oral pills, skin patches, and transdermal systems. This nanoparticle approach adds to that pipeline by showing that liraglutide can be reformulated to cross the skin barrier, which has historically been one of the hardest challenges in peptide drug delivery.
What This Study Doesn't Tell Us
This is an early-stage animal study using mice, so human skin penetration and efficacy are unproven. The abstract does not report specific numbers for weight loss, blood sugar reduction, or skin penetration rates. Long-term safety of the nanoparticle materials applied to skin is unknown. Scaling from laboratory to clinical manufacturing would require significant additional development.
Questions This Raises
- ?Can this nanoparticle system deliver enough liraglutide through human skin to match the therapeutic doses achieved by injection?
- ?How do the tannic acid and aluminum nanoparticle materials affect skin health with repeated long-term application?
- ?Could this platform be adapted for newer, more potent GLP-1 drugs like semaglutide or tirzepatide?
Trust & Context
- Key Stat:
- Needle-free GLP-1 delivery Nanoparticle-coated liraglutide penetrated skin barriers and produced sustained blood sugar and weight effects in mice
- Evidence Grade:
- This is a preliminary-evidence animal study. While it demonstrates a promising proof of concept for transdermal liraglutide delivery, results are limited to mouse models with no human data and no specific quantitative outcomes reported in the abstract.
- Study Age:
- Published in 2025, this is very recent research reflecting current advances in peptide delivery technology.
- Original Title:
- Enhanced Transdermal Delivery of Liraglutide for Sustained Obesity Management.
- Published In:
- Langmuir : the ACS journal of surfaces and colloids, 41(19), 12189-12198 (2025)
- Authors:
- Chen, Nipeng, Zeng, Zhipeng, Chen, Haolin, Liu, Hong, Zhang, Zhihui, Ke, Fangfang, Ji, Xiaoyu, Liu, Lixin, Zhang, Zhen, Chen, Yongming
- Database ID:
- RPEP-10403
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could this technology eliminate the need for GLP-1 injections?
Potentially, but it's very early. This study showed liraglutide can be delivered through mouse skin using specially designed nanoparticles, but human skin is different and clinical trials would be needed to confirm whether enough drug can be absorbed to match injection doses.
What makes delivering peptides through the skin so difficult?
The outer layer of skin (stratum corneum) is designed to keep molecules out. Peptide drugs like liraglutide are relatively large molecules that can't easily pass through this barrier on their own, which is why researchers used nanoparticles with a special coating to enhance penetration.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-10403APA
Chen, Nipeng; Zeng, Zhipeng; Chen, Haolin; Liu, Hong; Zhang, Zhihui; Ke, Fangfang; Ji, Xiaoyu; Liu, Lixin; Zhang, Zhen; Chen, Yongming. (2025). Enhanced Transdermal Delivery of Liraglutide for Sustained Obesity Management.. Langmuir : the ACS journal of surfaces and colloids, 41(19), 12189-12198. https://doi.org/10.1021/acs.langmuir.5c00949
MLA
Chen, Nipeng, et al. "Enhanced Transdermal Delivery of Liraglutide for Sustained Obesity Management.." Langmuir : the ACS journal of surfaces and colloids, 2025. https://doi.org/10.1021/acs.langmuir.5c00949
RethinkPeptides
RethinkPeptides Research Database. "Enhanced Transdermal Delivery of Liraglutide for Sustained O..." RPEP-10403. Retrieved from https://rethinkpeptides.com/research/chen-2025-enhanced-transdermal-delivery-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.